Subscribe to RoboticOncology.com RSS Feed

New Genomic Prostate Cancer Test Holds More Answers

NEW YORK, NY, May 9, 2013 -- Announcement of a new prostate cancer screener could answer the prostate cancer community's call for testing improvements. Unlike the prostate-specific antigen (PSA) test, the new Oncotype DX Prostate Cancer test uses advanced genetic methods to more accurately distinguish between aggressive prostate cancer and low-risk prostate cancer. The breakthrough, according to Dr. David Samadi, may be just what's needed for better risk assessment and more targeted prostate cancer treatment planning.

The Oncotype DX prostate cancer test was introduced this week at the annual meeting of the American Urological Association where Dr. Samadi, Chief of Robotics and Minimally Invasive Surgery and Vice Chairman of the Department of Urology at The Mount Sinai Medical Center, is also presenting information.Genomic Health, maker of the Oncotype DX, claims the new test will significantly improve prostate cancer staging. If so, prostate cancer experts and men could soon be making more informed treatment decisions regarding popular choices like watchful waiting and robotic prostate surgery.

Building on the success of their genetic breast cancer screener, Genomic Health designed the new prostate cancer test to analyze the activity levels of 17 cancer-related genes and five control genes. Gene inclusion was based on impact on cell growth, androgen hormone metabolism, and additional tumor-related processes.

"If we continue routine PSA screening, advanced genetic tests like this one could be the perfect intermediate step before a prostate biopsy," suggested Dr. Samadi. "Ultimately, men who undergo biopsy and prostate surgery will have even greater assurance that they're taking the right steps for lifelong wellness."

Prior to launch, Genomic Health evaluated the biopsy samples of 400 men whose cancerous prostates were removed and previously deemed low risk during post-surgery analysis. In re-testing the samples with the Oncotype DX, researchers were able to match the results in 50 percent of the cases.

"The more we do to help patients make individual, informed prostate cancer treatment decisions, the better," said Dr. Samadi. "I look forward to the results of further Oncotype DX testing and other genetic evaluators to come."
 
David B. Samadi, MD
1-855-DRSAMADI
1-212-241-8779

Back to Press Releases


Bookmark Using:
Facebook Twitter LinkedIn Email Yahoo

Share on Facebook

Call to Make an Appointment With Dr. David Samadi:

1-212-365-5000

Click the contact link to learn how Dr. Samadi can help treat your prostate cancer and give you back your quality of life.

* The benefits of robotic surgery cannot be guaranteed as surgery is both patient and procedure specific. Previous surgical results do not guarantee future outcomes.




Testimonials
R. P., New York, USA

From the time I arrived at Mount Sinai for my operation until the time I left for home, about 26 hours later, I was treated efficiently, professionally, and compassionately by all I came in contact with...

more..
Bob B. New Milford, USA

Thanks to Dr. David Samadi and the staff at Mt. Sinai Hospital for giving me my life back.

more..
V. S., Spain

My story is surely the same as hundreds of patients that have gone before me, and hundreds more than will come after me. I feel, however, an uncontrollable desire to tell this story, hoping it helps someone who is in the same situation that I was and that they find it inspirational enough to make a decision that will help them feel reborn...

more..
John, New York,USA

My urologist then referred me to Dr. David Samadi, Chief of Robotics and Minimally Invasive Surgery at Mt. Sinai Hospital, specializing in urological oncology, robotic surgery, and development of the Da Vinci technique. He had performed over 1500 surgeries successfully.

more..